(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
This Week In Space podcast: Episode 188 — A New NASA Leader Rises? - 2Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 3Best Amusement Park Bite: What Do You Very much want to Crunch On?
- 4This Tiny Neon Frog Dwells in the Clouds
- 5Well known Travel Booking Locales: What's Your Pick?
- 5 Indoor Plants That Further develop Air Quality
- Understanding the Rudiments of Tree Administrations
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- Can a mammogram help identify heart disease?
- Astronauts' brains change shape and position after time in space, study finds
- Favored Vehicle for Seniors: Make Your Determination
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Space station changes command, setting stage for Crew 11 departure
